Kintor Pharma Announces Completion of First Patient Enrollment in KX-826 Long-term Safety Phase III Trial for Treatment of AGA
    Research/Science 7/19/2023

    At a glance
    In this general discussion post the tone is ๐Ÿ˜ neutral.

    Other terms

    Kintor Pharma has finished enrolling the first patient in a Phase III trial for KX-826, a treatment for androgenetic alopecia (AGA). One user has set a reminder to check back on the topic in a year.
    View this post in the Community โ†’

    Similar Community Posts Join

    5 / 182 results

    Related Research

    6 / 124 results